Andere talen ARS Pharmaceuticals, Inc.

Aandelen

SPRY

US82835W1080

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
8,7 ^USD	+1,16%		+2,35%	+58,76%

18/04	ARS Pharmaceuticals Insider verkocht aandelen ter waarde van $928.005, volgens een recente SEC filing	MT
18/04	ARS Pharmaceuticals Insider verkocht aandelen ter waarde van $928.005, volgens een recent SEC-document	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand	30/04
ARS Pharmaceuticals, Inc. Submits Response for Neffy (Epinephrine Nasal Spray) Marketing Authorization Application to EMA's Chmp	30/04
Ars Pharmaceuticals, Inc. Enters Exclusive License and Distribution Agreement with CSL Seqirus for Commercialization of Neffy in Australia and New Zealand	30/04
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	18/04
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	10/04
ARS Pharmaceuticals Files Response to FDA Complete Response Letter For Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Letter for Neffy	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Submits Response to FDA Complete Response Letter for Neffy® (Epinephrine Nasal Spray)	03/04
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	21/03
ARS Pharmaceuticals, Inc.(NasdaqGM:SPRY) added to S&P Biotechnology Select Industry Index	18/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy Investor Day	08/03
ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day	07/03
ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024	06/03
North American Morning Briefing : Stock Futures -2-	06/03
ARS Pharmaceuticals announces neffy meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	27/02
ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study	26/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen ARS Pharmaceuticals, Inc.

Aandelen

SPRY

US82835W1080

Andere talen

Filters